Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q12887

UPID:
COX10_HUMAN

ALTERNATIVE NAMES:
Heme O synthase

ALTERNATIVE UPACC:
Q12887; B2R6U5; B4DJ50; O15334; Q969F7

BACKGROUND:
Heme O synthase, or Protoheme IX farnesyltransferase, is essential for mitochondrial energy metabolism, catalyzing the synthesis of heme O from protoheme IX and farnesyl diphosphate. Its role is fundamental in maintaining mitochondrial integrity and function.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Protoheme IX farnesyltransferase could open doors to potential therapeutic strategies for combating Mitochondrial complex IV deficiency, nuclear type 3. This disease's association with the enzyme offers a promising avenue for drug discovery and development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.